Clinical Trial Update: NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

Elisigen, Inc. reports a Phase 1/2 clinical trial evaluating NG101, an AAV gene therapy, for wet age-related macular degeneration. The study is currently ACTIVE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• NG101

Snippet

Sponsor: Elisigen, Inc. | Conditions: Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING